Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
about
Adverse effects of antiretroviral therapy for HIV infectionIncidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortIs Liver Enzyme Release Really Associated with Cell Necrosis Induced by Oxidant Stress?Therapeutic issues in HIV/HCV-coinfected patientsSeroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, TanzaniaCoinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical OutcomesAdverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationLiver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.Hepatic profile analyses of tipranavir in Phase II and III clinical trialsHepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.Seroprevalence of HBV and HIV co-infection in children and outcomes following highly active antiretroviral therapy (HAART) in Uyo, South-South NigeriaHepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or CFactors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAARTDevelopment of fatal acute liver failure in HIV-HBV coinfected patients.Hepatitis B and hepatitis C co-infection in patients with HIV.Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literatureAntithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study.Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000.Liver transplantation in HCV/HIV positive patients.Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV.Hepatitis C and human immunodeficiency virus infection.Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection.HIV viral suppression in the era of antiretroviral therapyImpact of hepatitis coinfection on healthcare utilization among persons living with HIV.Risk factors for idiosyncratic drug-induced liver injury.Hepatitis C and HIV-1 coinfection.HIV-1, HCV and alcohol in the CNS: potential interactions and effects on neuroinflammation.Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort studyAssessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in ThailandNew hopes for HIV and HCV coinfection in 2004.Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.Liver enzymes elevation after HAART in HIV-HCV co-infection.Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsProgression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.Treatment of hepatitis C in HIV-coinfected patients.
P2860
Q24617882-3C2919B2-AE7E-4591-85B3-08A62E83E015Q24814420-E9409525-8FE4-4DAC-88C9-6D9D2E313388Q26769973-D862CD99-DF9E-4FB1-A2DC-C24ECC321B4BQ27481053-51827954-1333-467B-8982-090725B798C8Q27485160-8D84122A-0D1C-4667-9EBE-4DDBB8FBD6EFQ27488883-824DC65D-9E1A-4B42-BCFB-364096EAB1E0Q28749406-A16027C4-E0E1-42AD-978C-BEC25ABC78F8Q30843946-A1406B54-85FD-4FF5-AB0E-60A05468EF73Q33518011-51C70F17-69D7-4354-A5AF-4DD2D7CFCF9DQ33535469-858E5DF4-4B9D-456F-A5F1-63071E1A242AQ33587716-20A1FE94-1B29-4392-9995-413E0333A9ADQ33609481-E3B2470F-A129-4597-AEC0-0085BDF83361Q33751609-B3EF3111-2E34-4B1B-A36D-5CFFFFB89B48Q33940800-275490E2-AAAC-4383-A1FD-DBE7ACEAA5B3Q34070485-8DB0DFAD-7B26-470A-AFF7-43D0D25426F7Q34084999-294EBE0A-33AB-4D40-90EF-BB66DFA2C060Q34323219-D59A8121-5A48-4B8E-8CC0-F7DAE979C5FAQ34349036-5D8F199F-BD7C-49F4-89EE-2CC1F96AB36AQ34444338-1CF9382D-3585-4F29-B2D1-7E7BB341CB36Q34571094-67B8AB92-F82C-4945-A498-59089BF5B271Q34614976-5548F1B2-39FA-4CB1-B405-F7A0773C0BDEQ34640985-EAD7EF23-DA1A-42AD-8D5F-0CCEA45DCB56Q34785683-AB0A3FBD-AA23-4EE0-82B5-FA7C7AA47D2EQ34789841-4C2DE59E-D4A3-43FC-AD1F-BB0AB669576BQ34984125-EBFB1A27-542F-44F4-83D0-6081B755D5ABQ34998102-31BB631B-E884-43E8-A263-EBCEBCE76DDFQ35059337-4DE360B1-8DA4-4A2F-938F-B73B4A8BEE11Q35106985-08F3CB58-0897-4020-ABF3-BB4885D0CF37Q35168108-110E41B6-3691-4F5D-AC80-B69A4E462B0EQ35595027-2367923C-A04F-4128-AFB0-46D520792D0FQ35596364-161EBE3F-9519-4478-A28B-F857628EFFE2Q35635844-D4F18E5F-DAA3-4F33-B1C5-D81CF9DB1AE9Q35809610-04413CE1-EF1D-46F3-BF1B-27F5656E4E28Q35883375-43725E55-2891-4CD1-A8AE-C31ABDA5C198Q35912407-116DED24-97DA-477F-8510-5F80E8D5CF2AQ36088274-ACEBD49D-115D-494C-AF02-73A5A4436722Q36177726-3F1F0FE3-6CFD-42CB-85C0-1AFFE1AEAFACQ36276597-AA479544-CE8E-4164-B0F8-C071B243806FQ36402487-765084BC-0304-4574-8109-2D4392E9E4B5Q36409500-9AC49919-8C6B-4818-A037-AD10DB682214
P2860
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Hepatitis B and C virus co-inf ...... al therapy in HIV-1 infection.
@en
Hepatitis B and C virus co-inf ...... al therapy in HIV-1 infection.
@nl
type
label
Hepatitis B and C virus co-inf ...... al therapy in HIV-1 infection.
@en
Hepatitis B and C virus co-inf ...... al therapy in HIV-1 infection.
@nl
prefLabel
Hepatitis B and C virus co-inf ...... al therapy in HIV-1 infection.
@en
Hepatitis B and C virus co-inf ...... al therapy in HIV-1 infection.
@nl
P2093
P1433
P1476
Hepatitis B and C virus co-inf ...... al therapy in HIV-1 infection.
@en
P2093
G J Weverling
M den Brinker
N G Pakker
P M Wertheim-van Dillen
R van Leeuwen
S A Danner
P304
P356
10.1097/00002030-200012220-00011
P407
P577
2000-12-01T00:00:00Z